The association of TRIB3 and tumor immunity has been reported in other types of tumors [37,38]; for example, in colorectal cancer, TRIB3 can reduce CD8+ T cell infiltration and induce immune evasion by inhibiting the STAT1-CXCL10 axis, suggesting that TRIB3 may be an attractive therapeutic target for ‘warming up’ of immune-resistant ‘cold’ tumors [37]. This evidence concerns the gene CXCL10 and neoplasm.